Kodiak Sciences Inc. is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, Kodiak is focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Its ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, its bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and the company is expanding its early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA.
Company profile
Ticker
KOD
Exchange
Website
CEO
Victor Perlroth
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne • Denali Therapeutics ...
Former names
Oligasis, LLC
SEC CIK
Corporate docs
IRS number
270476525
KOD stock data
News
71 Biggest Movers From Yesterday
20 May 22
38 Stocks Moving In Thursday's Mid-Day Session
19 May 22
Kodiak Sciences Announces The Opening Of A New, Custom-built, Bioconjugation Facility Within Lonza's Ibex Dedicate Manufacturing Complex In Visp
19 May 22
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
19 May 22
24 Stocks Moving in Thursday's Pre-Market Session
19 May 22
Press releases
Thinking about buying stock in Chimerix, AT&T, Canada Goose, Kodiak Sciences, or Torm?
19 May 22
Grand Opening of Kodiak Sciences' Purpose-built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal Diseases
19 May 22
Kodiak Sciences Announces First Quarter 2022 Financial Results and Recent Business Highlights
10 May 22
Kodiak Sciences Announces Presentation of KSI-301 Phase 2b/3 Study Data in wet AMD at Upcoming Research Conferences
29 Apr 22
Kodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
1 Mar 22
Analyst ratings and price targets
Current price
Average target
$12.50
Low target
$7.00
High target
$21.00
Morgan Stanley
Maintains
$10.00
Goldman Sachs
Maintains
$7.00
Citigroup
Maintains
$12.00
JP Morgan
Downgraded
$21.00
Investment data
Securities sold
Number of investors
Calendar
10 May 22
24 May 22
31 Dec 22
Financial summary
| Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 678.05M | 678.05M | 678.05M | 678.05M | 678.05M | 678.05M |
| Cash burn (monthly) | 19.93M | 20.73M | 31.92M | 26.02M | 14.39M | 15.9M |
| Cash used (since last report) | 35.38M | 36.8M | 56.67M | 46.2M | 25.54M | 28.23M |
| Cash remaining | 642.67M | 641.25M | 621.38M | 631.85M | 652.51M | 649.82M |
| Runway (months of cash) | 32.3 | 30.9 | 19.5 | 24.3 | 45.4 | 40.9 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 18 May 22 | Baker Bros. Advisors | Common Stock | Buy | Acquire P | Yes | No | 5.9689 | 7,489 | 44.7K | 15,142,074 |
| 18 May 22 | Baker Bros. Advisors | Common Stock | Buy | Acquire P | Yes | No | 5.9689 | 912 | 5.44K | 1,245,661 |
| 18 May 22 | Baker Bros. Advisors | Common Stock | Buy | Acquire P | Yes | No | 5.9686 | 182,827 | 1.09M | 15,134,585 |
| 18 May 22 | Baker Bros. Advisors | Common Stock | Buy | Acquire P | Yes | No | 5.9686 | 22,266 | 132.9K | 1,244,749 |
| 18 May 22 | Baker Bros. Advisors | Common Stock | Buy | Acquire P | Yes | No | 5.9537 | 9,157 | 54.52K | 14,951,758 |
| 18 May 22 | Baker Bros. Advisors | Common Stock | Buy | Acquire P | Yes | No | 5.9537 | 1,115 | 6.64K | 1,222,483 |
| 17 May 22 | Baker Bros. Advisors | Common Stock | Buy | Acquire P | Yes | No | 5.9877 | 90,674 | 542.93K | 14,942,601 |
| 17 May 22 | Baker Bros. Advisors | Common Stock | Buy | Acquire P | Yes | No | 5.9877 | 11,043 | 66.12K | 1,221,368 |
| 17 May 22 | Baker Bros. Advisors | Common Stock | Buy | Acquire P | Yes | No | 5.9866 | 8,118 | 48.6K | 14,851,927 |
| 17 May 22 | Baker Bros. Advisors | Common Stock | Buy | Acquire P | Yes | No | 5.9866 | 989 | 5.92K | 1,210,325 |
Institutional ownership, Q1 2022
80.3% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 140 |
| Opened positions | 43 |
| Closed positions | 58 |
| Increased positions | 42 |
| Reduced positions | 40 |
| 13F shares | Current |
|---|---|
| Total value | 326.41M |
| Total shares | 41.74M |
| Total puts | 326.9K |
| Total calls | 627.2K |
| Total put/call ratio | 0.5 |
| Largest owners | Shares | Value |
|---|---|---|
| Baker Bros. Advisors | 15.93M | $122.99M |
| BLK Blackrock | 3.44M | $26.53M |
| Vanguard | 2.36M | $18.22M |
| Wellington Management | 1.46M | $11.24M |
| MS Morgan Stanley | 1.36M | $10.53M |
| Millennium Management | 1.06M | $8.15M |
| ICONIQ Capital | 1.02M | $7.85M |
| D. E. Shaw & Co. | 997.82K | $7.7M |
| Two Sigma Investments | 989.58K | $7.64M |
| STT State Street | 972.51K | $7.51M |
Financial report summary
?Competition
Novartis • Ocugen • Ocular Therapeutix • Kala Pharmaceuticals • Adverum Biotechnologies • Graybug Vision • Allergan • Regenxbio • 4D Molecular Therapeutics • Molecular PartnersContent analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
absent, accessible, acuity, adware, alleviate, authentication, Avastin, BCVA, branch, Brazil, clarify, Colorado, destruction, differentiated, dual, email, encryption, endothelial, Extortion, extracellular, facilitate, factor, Feb, hardware, imputed, incremental, inhibitor, intracellular, invasion, length, mammalian, military, misuse, notification, NPDR, offline, online, pathophysiology, pause, persistent, phosphorylcholine, photographic, presence, PSO, reactivation, recombinant, retaliatory, retreatment, Russia, Russian, server, sham, Shanghai, surge, theft, threat, tight, Ukraine, unchanged, undertreatment, unlawful, Utah, Vabysmo, variant, Virginia, visual
Removed:
accretion, adequacy, analyzing, anatomical, anesthesiologist, approving, ballot, beneficial, broaden, certification, certified, chart, codification, collection, Commerce, compromise, concurrent, context, contractually, conviction, correct, corruption, credit, DAZZLE, drying, Edition, enacting, encouraging, explicit, Exudation, fundamentally, genetic, globally, governance, headcount, immaterial, initially, insurer, interval, IPO, lawful, lesser, malfeasance, maturity, measure, measurement, notable, October, presentation, preventive, principle, ratably, realized, reclassified, reclassify, remediate, requisite, retina, robust, screening, Shield, topline, track, treasury, unrecognized, unvested, usability, valuation, vascular, Virtual, vision
Financial reports
Current reports
8-K
Kodiak Sciences Announces First Quarter 2022 Financial Results and Recent Business Highlights
10 May 22
8-K
Kodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
28 Feb 22
8-K
Results of Operations and Financial Condition
23 Feb 22
8-K
Kodiak Sciences Announces Third Quarter 2021 Financial Results and Recent Business Highlights
9 Nov 21
8-K
Summary of the LTPIP
15 Oct 21
8-K
Kodiak Sciences Announces New Long-Term Performance Incentive Plan
1 Sep 21
8-K
Kodiak Sciences Announces Second Quarter 2021 Financial Results and Recent Business Highlights
9 Aug 21
8-K
Entry into a Material Definitive Agreement
22 Jul 21
8-K
Submission of Matters to a Vote of Security Holders
7 Jun 21
8-K
Kodiak Sciences Announces First Quarter 2021 Financial Results and Recent Business Highlights
10 May 21
Registration and prospectus
S-8
Registration of securities for employees
10 May 22
S-8
Registration of securities for employees
15 Dec 21
S-3ASR
Automatic shelf registration
10 May 21
S-8
Registration of securities for employees
1 Mar 21
424B5
Prospectus supplement for primary offering
18 Nov 20
424B5
Prospectus supplement for primary offering
16 Nov 20
S-3ASR
Automatic shelf registration
16 Nov 20
424B3
Prospectus supplement
4 Dec 19
424B3
Prospectus supplement
3 Dec 19
S-3
Shelf registration
1 Nov 19
Proxies
DEFA14A
Additional proxy soliciting materials
27 Apr 22
DEFA14A
Additional proxy soliciting materials
5 Oct 21
PRE 14A
Preliminary proxy
1 Sep 21
DEFA14A
Additional proxy soliciting materials
1 Sep 21
DEFA14A
Additional proxy soliciting materials
28 Apr 21
DEFA14A
Additional proxy soliciting materials
28 Apr 20
DEF 14A
Definitive proxy
28 Apr 20
Other
EFFECT
Notice of effectiveness
15 Nov 19
CORRESP
Correspondence with SEC
11 Nov 19
UPLOAD
Letter from SEC
11 Nov 19
EFFECT
Notice of effectiveness
4 Oct 18
CERT
Certification of approval for exchange listing
2 Oct 18
CORRESP
Correspondence with SEC
30 Sep 18
CORRESP
Correspondence with SEC
30 Sep 18
CORRESP
Correspondence with SEC
26 Sep 18
UPLOAD
Letter from SEC
24 Sep 18
CORRESP
Correspondence with SEC
23 Sep 18
Ownership
4
Kodiak Sciences / JULIAN BAKER ownership change
18 May 22
SC 13D/A
Kodiak Sciences / BAKER BROS. ADVISORS ownership change
18 May 22
SC 13G/A
Kodiak Sciences / PRICE T ROWE ASSOCIATES ownership change
10 Mar 22
SC 13G/A
Kodiak Sciences / WELLINGTON MANAGEMENT ownership change
10 Mar 22
SC 13G/A
Kodiak Sciences / BlackRock ownership change
9 Mar 22
4
Kodiak Sciences / VICTOR PERLROTH ownership change
28 Feb 22
4
Kodiak Sciences / JASON EHRLICH ownership change
18 Feb 22
4
Kodiak Sciences / JOHN A. BORGESON ownership change
18 Feb 22
4
Kodiak Sciences / VICTOR PERLROTH ownership change
18 Feb 22
4
Kodiak Sciences / JULIAN BAKER ownership change
17 Feb 22
Patents
Utility
Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates And Their Preparation
31 Mar 22
The present invention relates to polymeric reagents and conjugates thereof, methods for synthesizing the polymeric reagents and conjugates, pharmaceutical compositions comprising the conjugates and methods of using the polymer conjugates including therapeutic methods where conjugates are administered to patients.
Utility
High Molecular Weight Zwitterion-containing Polymers
30 Dec 21
The present invention provides multi-armed high MW polymers containing hydrophilic groups and one or more functional agents, and methods of preparing such polymers.
Utility
Dual PDGF/VEGF antagonists
26 Oct 21
The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist.
Utility
Antibodies and Conjugates Thereof
21 Oct 21
Provided herein are anti-VEGF-A antibodies and antibody conjugates thereof.
Utility
Butyrylcholinesterase zwitterionic polymer conjugates
27 Jul 21
The present invention provides recombinant butyrylcholinesterase fusion proteins, including Fc fusion proteins and multi-armed high MW polymers containing hydrophilic groups conjugated to the fusion proteins, and methods of preparing such polymers.
Reddit threads
Daily Discussion Thread - May 9th, 2022
9 May 22
Dividend vs. non-dividend assets
8 May 22
Daily Discussion Thread - May 6th, 2022
6 May 22
What do you guys think of Lithium stocks right now are such big gains YoY? $LITOF
23 Apr 22
Companies with great cash reserves that have lost value
23 Mar 22
Goodnight stock portfolio
24 Feb 22
Morning Update for Wednesday, 2/23/22
23 Feb 22
What’s one penny stock you had in your portfolio but sold before it surged in the market?
22 Feb 22
Breakouts and Breakdowns Scanner Thread for January 25th, 2022
25 Jan 22
Breakouts and Breakdowns Scanner Thread for January 24th, 2022
24 Jan 22